DOCSLIB.ORG

Postmenopausal Hormone Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Postmenopausal Hormone Therapy PL Detail-Document #280506 −This PL Detail-Document gives subscribers additional insight related to the Recommendations published in− PHARMACIST’S LETTER / PRESCRIBER’S LETTER May 2012 Postmenopausal Hormone Therapy Brand Name Generic Name Available Strengths e Estrogen Type of (Dosing Interval for Source 1 Estrogen 1 Topicals) e Estradiol-containing products 2,3,6 Activella estradiol/norethindrone 0.5 mg estradiol and Synthetic Human a U.S. only acetate tablet 0.1 mg norethindrone, generic available 1 mg estradiol and 0.5 mg norethindrone Alora estradiol transdermal 0.025 mg/24 hr, Synthetic Human a U.S. only system 0.05 mg/24 hr, (twice weekly) 0.075 mg/24 hr, 0.1 mg/24 hr Angeliq estradiol/drospirenone 0.5 mg estradiol and Synthetic Human a tablet 0.25 mg drospirenone (U.S.),g 1 mg estradiol and 0.5 mg drospirenone (U.S.), 1 mg estradiol and 1 mg drospirenone (Canada) Climara estradiol transdermal 0.025 mg/24 hr, Synthetic Human a generic system 0.0375 mg/24 hr (U.S. only), available-U.S. (once weekly) 0.05 mg/24 hr, 0.06 mg/24 hr (U.S. only), 0.075 mg/24 hr, 0.1 mg/24 hr Climara Pro estradiol/levonorgestrel 0.045 mg estradiol and Synthetic Human a transdermal system 0.015 mg levonorgestrel/24 hr (once weekly) CombiPatch estradiol/norethindrone 0.05 mg estradiol and Synthetic Human a U.S. only acetate transdermal 0.14 mg norethindrone/24 hr, system 0.05 mg estradiol and (twice weekly) 0.25 mg norethindrone/24 hr Divigel 17-beta-estradiol 0.1% Synthetic Human a U.S. only transdermal gel (0.25 g/packet = 0.25 mg estradiol, (once daily) 0.5 g/packet = 0.5 mg estradiol, 1 g/packet = 1 mg estradiol) Elestrin estradiol gel 0.06% Synthetic Human a U.S. only (once daily) (estradiol 0.53 mg/metered dose) Estrace 17-beta-estradiol, 0.5 mg, 1 mg, 2 mg Synthetic Human a generic micronized tablet available-U.S. Estrace 17-beta-estradiol 0.01% estradiol Synthetic Human a vaginal cream vaginal cream (0.1 mg/gram) U.S. only (varies) Estraderm estradiol transdermal 0.025 mg/24 hr, Synthetic Human a Canada only system 0.1 mg/24 hr generic available (twice weekly) More. Copyright © 2012 by Therapeutic Research Center P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249 www.pharmacistsletter.com ~ www.prescribersletter.com ~ www.pharmacytechniciansletter.com (PL Detail-Document #280506: Page 2 of 5) Brand Name Generic Name Available Strengths e Estrogen Type of (Dosing Interval for Source 1 Estrogen 1 Topicals) e Estradiol-containing products,2,3,6 continued Estradot estradiol transdermal 0.025 mg/24 hr, 0.0375 mg/24 hr, Synthetic Human a Canada only system 0.05 mg/24 hr, 0.075 mg/24 hr, (twice weekly) 0.1 mg/24 hr Estrasorb estradiol topical emulsion 0.25% Synthetic Human a U.S. only (once daily) Estring 17-beta-estradiol 0.0075 mg/24 hr Synthetic Human a vaginal ring (once every three months) EstroGel 17-beta-estradiol 0.06% Synthetic Human a micronized gel (estradiol 0.75 mg/metered dose) (once daily) Evamist 17-beta-estradiol Estradiol 1.53 mg/spray Synthetic Human a U.S. only transdermal spray (once daily) Femhrt ethinyl estradiol/ 0.0025 mg ethinyl estradiol and Synthetic Human a norethindrone acetate 0.5 mg norethindrone (U.S. only), tablet 0.005 mg ethinyl estradiol and 1 mg norethindrone Femring estradiol acetate vaginal 0.05 mg/24 hr, Synthetic Human a U.S. only ring 0.1 mg/24 hr (once every three months) Femtrace estradiol acetate tablet 0.45 mg, 0.9 mg Synthetic Human a U.S. only Menostar estradiol transdermal 14 mcg/24 hr Synthetic Human a U.S. only system (once weekly) Oesclim estradiol transdermal 0.025 mg/24 hr, Synthetic Human a Canada only system 0.0375 mg/24 hr, (twice weekly) 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr Prefest estradiol/norgestimate 1 mg estradiol and Synthetic Human a U.S. only tablet 1 mg estradiol/0.09 mg norgestimate b estradiol hemihydrate 10 mcg estradiol, Synthetic Human a Vagifem vaginal tablet 25 mcg estradiol (Canada only) (twice weekly) Vivelle-Dot estradiol transdermal 0.025 mg/24 hr, Synthetic Human a U.S. only system 0.0375 mg/24 hr, (twice weekly) 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr More. Copyright © 2012 by Therapeutic Research Center P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249 www.pharmacistsletter.com ~ www.prescribersletter.com ~ www.pharmacytechniciansletter.com (PL Detail-Document #280506: Page 3 of 5) Brand Name Generic Name Available Strengths e Estrogen Type of (Dosing Interval for Source 1 Estrogen 1 Topicals) e Conjugated estrogens-containing products 2,3,6 C.E.S. synthetic conjugated 0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg Synthetic, Equine Canada only estrogens tablet plant-derived generic available Cenestin synthetic conjugated 0.3 mg, 0.45 mg, 0.625 mg, Synthetic, Equine U.S. only estrogens, A tablet 0.9 mg, 1.25 mg plant-derived Enjuvia synthetic conjugated 0.3 mg, 0.45 mg, 0.625 mg, Synthetic, Equine U.S. only estrogens, B tablet 0.9 mg, 1.25 mg plant-derived PMS- conjugated estrogens 0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg Pregnant mare Equine Conjugated tablet urine-derived Estrogens Canada only Premarin conjugated estrogens 0.3 mg, 0.45 mg (U.S. only), Pregnant mare Equine tablet 0.625 mg, 0.9 mg (U.S. only), urine-derived 1.25 mg Premarin conjugated estrogens 0.625 mg/gram Pregnant mare Equine vaginal cream vaginal cream urine-derived (once daily) Premphase conjugated estrogens/ 0.625 mg conjugated estrogens and Pregnant mare Equine U.S. only medroxyprogesterone 0.625 mg conjugated estrogens/ urine-derived acetate tablet 5 mg medroxyprogesterone c Prempro conjugated estrogens/ 0.3 mg conjugated estrogens and Pregnant mare Equine U.S. only medroxyprogesterone 1.5 mg medroxyprogesterone, urine-derived acetate tablet 0.45 mg conjugated estrogens and 1.5 mg medroxyprogesterone, 0.625 mg conjugated estrogens and 2.5 mg medroxyprogesterone, 0.625 mg conjugated estrogens and 5 mg medroxyprogesterone Esterified estrogen-containing products 2,3,6 Covaryx f esterified estrogens/ 1.25 mg esterified estrogens and Synthetic Equine U.S. only methyltestosterone tablet 2.5 mg methyltestosterone generic available Covaryx HS f esterified estrogens/ 0.625 mg esterified estrogens and Synthetic Equine U.S. only methyltestosterone tablet 1.25 mg methyltestosterone generic available Estragyn d estrone vaginal cream 1 mg/gram Synthetic Human a vaginal cream (once daily) soy-derived Canada only Menest esterified estrogens tablet 0.3 mg, 0.625 mg, 1.25 mg, 2.5 mg Synthetic Human a + U.S. only 75% to 85% estrone soy-derived Equine + 6% to 15% equilin Estropipate-containing products (piperazine estrone sulfate) 2,3,6 Ogen estropipate tablet 0.75 mg ( Ogen .625 ), Synthetic Human a generic 1.5 mg ( Ogen 1.25 ), available-U.S. 3 mg ( Ogen 2.5 ) More. Copyright © 2012 by Therapeutic Research Center P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249 www.pharmacistsletter.com ~ www.prescribersletter.com ~ www.pharmacytechniciansletter.com (PL Detail-Document #280506: Page 4 of 5) Brand Name Generic Name Available Strengths e Estrogen Type of (Dosing Interval for Source 1 Estrogen 1 Topicals) e Compounded estrogen products (See FDA statement concerning the unapproved drug ESTRIOL [http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm183088.ht m]) Biest 4,5 bi-estrogen Typically 2 mg estriol/0.5 mg Variable Human a estradiol, but can vary by pharmacy Triest 4,5 tri-estrogen Typically 1 mg estriol/0.125 mg Variable Human a estradiol/0.125 mg estrone a. Human or bioidentical implies exogenous hormones that are identical to endogenous hormones found in humans. b. Regimen consists of continuous cycles of three days of 1 mg estradiol followed by three days 1 mg estradiol and 0.09 mg norgestimate. 7 c. Regimen consists of continuous cycle of 14 days of 0.625 mg conjugated estrogens followed by 14 days of 0.625 mg conjugated estrogens and 5 mg medroxyprogesterone. 8 d. Formerly marketed as Neo-Estrone by Neolab. e. Dose frequency and formulation information from most current product labeling at time of publication. f. Considered an “unapproved drug” by the FDA. g. New low-dose Angeliq (0.5/0.25) is expected to be available in the U.S. summer 2012. Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication. More. Copyright © 2012 by Therapeutic Research Center P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249 www.pharmacistsletter.com ~ www.prescribersletter.com ~ www.pharmacytechniciansletter.com (PL Detail-Document #280506: Page 5 of 5) Project Leader in preparation of this PL Detail- 3. Drugs@FDA. Document: Stacy A. Hester, R.Ph., BCPS, http://www.accessdata.fda.gov/scripts/cder/drugsat fda/. (Accessed April 12, 2012). Assistant Editor 4. PL Detail-Document , Bioidentical Hormones. Pharmacist’s Letter/Prescriber’s Letter . October References 2003. 1. North American Menopause Society. Menopause 5.
Load more

Recommended publications
  • MENEST ® Brand of Esterified Estrogens Tablets, USP
    PRESCRIBING INFORMATION MENEST ® brand of esterified estrogens tablets, USP WARNINGS 1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA. Three independent case control studies have shown an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for prolonged periods.1–3 This risk was independent of the other known risk factors for endometrial cancer. These studies are further supported by the finding that incidence rates of endometrial cancer have increased sharply since 1969 in eight different areas of the United States with population-based cancer reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade.4 The three case control studies reported that the risk of endometrial cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment1 and on estrogen dose.3 In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible. When prolonged treatment is medically indicated, the patient should be reassessed on at least a semiannual basis to determine the need for continued therapy. Although the evidence must be considered preliminary, one study sug- gests that cyclic administration of low doses of estrogen may carry less risk than continuous administration3; it therefore appears prudent to utilize such a regimen. Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or recurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy.
    [Show full text]
  • Estradiol Acetate Vaginal Ring) Rx Only
    NDA 21-367/S-002 Page 3 PRESCRIBING INFORMATION Femring® (estradiol acetate vaginal ring) Rx Only ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (See WARNINGS, Malignant neoplasms, Endometrial cancer.) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. (See WARNINGS, Cardiovascular disorders and Dementia.) The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical Studies and WARNINGS, Cardiovascular disorders and Malignant neoplasms, Breast cancer.) The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens
    [Show full text]
  • Estrogen Agents, Oral-Transdermal
    GEORGIA MEDICAID FEE-FOR-SERVICE ESTROGEN AGENTS, ORAL - TRANSDERMAL PA SUMMARY Preferred Non-Preferred Oral Estrogens Estradiol generic n/a Menest (esterified estrogens) Premarin (estrogens, conjugated) Oral Estrogen/Progestin Combinations Angeliq (drospirenone/estradiol) Bijuva (estradiol/progesterone) Estradiol/norethindrone and all generics for Activella Norethindrone/ethinyl estradiol and all generics for Femhrt Low Dose 0.5/2.5 (norethindrone/ethinyl Femhrt Low Dose estradiol) Jinteli and all generics for Femhrt 1/5 (norethindrone/ethinyl estradiol) Prefest (estradiol/norgestimate) Premphase (conjugated estrogens/medroxyprogesterone) Prempro (conjugated estrogens/medroxyprogesterone) Topical Estrogens Alora (estradiol transdermal patch) Divigel (estradiol topical gel) Estradiol transdermal patch (generic Climara) Elestrin (estradiol topical gel) Evamist (estradiol topical spray solution) Estradiol transdermal patch (generic Vivelle-Dot) Menostar (estradiol transdermal patch) Minivelle (estradiol transdermal patch) Vivelle-Dot (estradiol transdermal patch) Topical Estrogens/Progestin Combination Climara Pro (estradiol/levonorgestrel transdermal patch) n/a Combipatch (estradiol/norethindrone transdermal patch) Oral Selective Estrogen Receptor Modulator (SERMs) Raloxifene generic Duavee (conjugated estrogens/bazedoxifene) Osphena (ospemifene) LENGTH OF AUTHORIZATION: 1 year PA CRITERIA: Bijuva ❖ Approvable for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus who have experienced inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects to at least two preferred oral estrogen/progestin combination products. Revised 6/29/2020 Norethindrone/Ethinyl Estradiol and All Generics for Femhrt Low Dose ❖ Prescriber must submit a written letter of medical necessity stating the reasons at least two preferred oral estrogen/progestin combination products, one of which must be brand Femhrt Low Dose, are not appropriate for the member.
    [Show full text]
  • Ambetter 90-Day-Maintenance Drug List- 2020
    Ambetter 90-Day-Maintenance Drug List Guide to this list: What is Ambetter 90‐Day‐Maintenance Drug List? Ambetter 90‐Day‐Supply Maintenance Drug List is a list of maintenance medications that are available for 90 day supply through mail order or through our Extended Day Supply Network. How do I find a pharmacy that is participating in Extended Day Supply Network? To find a retail pharmacy that is participating in our Extended Day Supply Network please consult information available under Pharmacy Resources tab on our webpage. Alternatively, you can utilize our mail order pharmacy. Information on mail order pharmacy is available in Pharmacy Resources tab on our webpage. Are all formulary drugs covered for 90 day supply? No, certain specialty and non‐specialty drugs are excluded from 90 day supply. Please consult 90‐Day‐ Supply Maintenance Drug List for information if your drug is included. A Amitriptyline HCl Acamprosate Calcium Amlodipine Besylate Acarbose Amlodipine Besylate-Atorvastatin Calcium Acebutolol HCl Amlodipine Besylate-Benazepril HCl Acetazolamide Amlodipine Besylate-Olmesartan Medoxomil Albuterol Sulfate Amlodipine Besylate-Valsartan Alendronate Sodium Amlodipine-Valsartan-Hydrochlorothiazide Alendronate Sodium-Cholecalciferol Amoxapine Alfuzosin HCl Amphetamine-Dextroamphetamine Aliskiren Fumarate Anagrelide HCl Allopurinol Anastrozole Alogliptin Benzoate Apixaban Alosetron HCl Arformoterol Tartrate Amantadine HCl Aripiprazole Amiloride & Hydrochlorothiazide Armodafinil Amiloride HCl Asenapine Maleate Amiodarone HCl Aspirin-Dipyridamole
    [Show full text]
  • Hormonal and Non-Hormonal Management of Vasomotor Symptoms: a Narrated Review
    Central Journal of Endocrinology, Diabetes & Obesity Review Article Corresponding authors Orkun Tan, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology Hormonal and Non-Hormonal and Infertility, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 75390 and ReproMed Fertility Center, 3800 San Management of Vasomotor Jacinto Dallas, TX 75204, USA, Tel: 214-648-4747; Fax: 214-648-8066; E-mail: [email protected] Submitted: 07 September 2013 Symptoms: A Narrated Review Accepted: 05 October 2013 Orkun Tan1,2*, Anil Pinto2 and Bruce R. Carr1 Published: 07 October 2013 1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology Copyright and Infertility, University of Texas Southwestern Medical Center, USA © 2013 Tan et al. 2Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, ReproMed Fertility Center, USA OPEN ACCESS Abstract Background: Vasomotor symptoms (VMS; hot flashes, hot flushes) are the most common complaints of peri- and postmenopausal women. Therapies include various estrogens and estrogen-progestogen combinations. However, both physicians and patients became concerned about hormone-related therapies following publication of data by the Women’s Health Initiative (WHI) study and have turned to non-hormonal approaches of varying effectiveness and risks. Objective: Comparison of the efficacy of non-hormonal VMS therapies with estrogen replacement therapy (ERT) or ERT combined with progestogen (Menopausal Hormone Treatment; MHT) and the development of literature-based guidelines for the use of hormonal and non-hormonal VMS therapies. Methods: Pubmed, Cochrane Controlled Clinical Trials Register Database and Scopus were searched for relevant clinical trials that provided data on the treatment of VMS up to June 2013.
    [Show full text]
  • 36148 Federal Register / Vol
    36148 Federal Register / Vol. 85, No. 115 / Monday, June 15, 2020 / Rules and Regulations Sundstrand) model 54H60 propellers with a collection of information subject to the Administration (NARA). For information on blade having a serial number (S/N) below requirements of the Paperwork Reduction the availability of this material at NARA, S/N 813320. Act unless that collection of information email: [email protected], or go to: displays a currently valid OMB Control https://www.archives.gov/federal-register/cfr/ (d) Subject Number. The OMB Control Number for this ibr-locations.html. Joint Aircraft System Component (JASC) information collection is 2120–0056. Public Issued on June 3, 2020. Code 6111, Propeller Blade Section. reporting for this collection of information is estimated to be approximately 1 hour per Lance T. Gant, (e) Unsafe Condition response, including the time for reviewing Director, Compliance & Airworthiness This AD was prompted by the separation instructions, searching existing data sources, Division, Aircraft Certification Service. of a propeller blade that resulted in the loss gathering and maintaining the data needed, [FR Doc. 2020–12821 Filed 6–12–20; 8:45 am] of an airplane and 17 fatalities. The FAA is completing and reviewing the collection of BILLING CODE 4910–13–P issuing this AD to detect cracking in the information. All responses to this collection propeller blade taper bore. The unsafe of information are mandatory. Send condition, if not addressed, could result in comments regarding this burden estimate or failure of the propeller blade, blade any other aspect of this collection of DEPARTMENT OF JUSTICE separation, and loss of the airplane.
    [Show full text]
  • Table E-46. Therapies Used in Trials Comparing Hormone with Placebo Ar Est Study N Rxcat Dose Route Generic Trade M Dose Martin 1971 1 56 Plac Oral
    Table E-46. Therapies used in trials comparing hormone with placebo Ar Est Study N RxCat Dose Route Generic Trade m Dose Martin 1971 1 56 Plac Oral Standar 2 53 EP seq 0.025 mg E + 1 mg P Oral mestranol + norethindrone d 3 56 EP seq 0.05 mg E + 1 mg P Oral mestranol + norethindrone High Campbell 1 68 Plac Oral 1977 2 68 Est 1.25 mg Oral conjugated equine estrogens Premarin High Baumgardner 1 42 Plac Oral 1978 2 42 Est 0.1 mg Oral quinestrol Estrovis Low Standar 3 35 Est 0.2 mg Oral quinestrol Estrovis d 4 37 Est 1.25 mg Oral conjugated estrogen Premarin High E-65 Ar Est Study N RxCat Dose Route Generic Trade m Dose Coope 1981 1 26 Plac Oral UltraLo 2 29 Est 0.3mg Oral piperazine estrone sulphate w Jensen 1983 1 90 Plac Oral estradiol + estriol + 2 41 EP seq 4 mg E + 1 mg P Oral Trisequens Forte High norethisterone acetate Foidart 1991 1 53 Plac VagPes Ortho-Gynest- 2 56 Est 1 mg VagPes estriol Low Depot Eriksen 1992 1 79 Plac VagTab 2 75 Est 0.025 mg VagTab estradiol Vagifem Low Wiklund 1993 11 1 Plac Patch 1 11 Standar 2 Est 0.05 mg Patch estradiol 2 d Derman 1995 1 42 Plac Oral Standar 2 40 EP seq 2 mg E + 1 mg P Oral estradiol + norethindrone acetate Trisequens d Saletu 1995 1 32 Plac Patch Standar 2 32 Est 0.05 mg Patch estradiol Estraderm d Good 1996 1 91 Plac Patch Standar 2 88 Est 0.05 mg Patch estradiol Alora d 3 94 Est 0.10 mg Patch estradiol Alora High Speroff (Study 1) 1 54 Plac Patch 1996 UltraLo 2 54 Est 0.02 mg Patch estradiol FemPatch w E-66 Ar Est Study N RxCat Dose Route Generic Trade m Dose Chung 1996 1 40 Plac Oral Standar
    [Show full text]
  • Female Hormone Therapy Options
    WOMEN’S INTERNATIONAL PHARMACY FEMALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women’s International Pharmacy staff pharmacists to represent some of the more frequently prescribed regimens for women in menopause and some alternatives. The Women’s International Pharmacy logo is placed throughout the tables to signify the hormones and dosage forms Women’s International Pharmacy compounds. This material is for informational purposes. It is not intended as a substitute for medical advice. Please consult a qualified health care professional for individual health and medical advice. = Compounded by Women’s International Pharmacy Oral Estrogens ORAL ESTROGENS DOSAGES DOSING BIOIDENTICAL AVAILABLE REGIMEN COMMENTS/REFERENCES Estradiol (E2) capsules Any 0.25mg - 2mg once Hargrove J. Infertility & Reproductive (compounding pharmacies) daily. Some may Med Clinic North America 1995; require twice daily 6(4):653-674. dosing. Estriol (E3) capsules Any 1mg - 8mg Head K. Alt Med Rev; 1998; 3(2):101- (compounding pharmacies) once daily or in 113. Hudson T. Women’s Encyclopedia divided doses. of Natural Medicine (Lincolnwood, IL: Keats) 1999:170. Biestrogen (bi-est) capsules Any 1.25mg - 5mg once The 20:80 ratio may be altered to meet 20% estradiol (E2), to twice daily patient need. 80% estriol (E3) McKenna S. The Phytogenic Hormone (compounding pharmacies) Solution (NYC, NY: Villard Books) 2002:189-190. Triestrogen (tri-est, triple 1.25mg - 2.5mg once Although these ratios are commonly Any estrogen) capsules to twice daily used and are based on the research 10% estrone (E1), done by Dr. Jonathan Wright, other formulas are available to accommodate 10% estradiol (E2), individual needs.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,071,531 Jona Et Al
    USOO6071531A United States Patent (19) 11 Patent Number: 6,071,531 Jona et al. (45) Date of Patent: Jun. 6, 2000 54) TRANSDERMAL PATCH AND METHOD FOR 5,376,377 12/1994 Gale et al.. ADMINISTERING 17-DEACETYL 5,393,529 2/1995 Hoffmann et al... NORGESTIMATE ALONE OR IN 5,422,119 6/1995 Casper. COMBINATION WITH AN ESTROGEN 5,474,783 12/1995 Miranda et al.. 5,508,038 4/1996 Wang et al.. 5,560,922 10/1996 Chien et al.. Inventors: Janan Jona, Sunnyvale; Jay Audett, 5,656.286 8/1997 Miranda et al.. Mountain View; Noel Singh, San 5,665,377 9/1997 Gonella et al.. Francisco, all of Calif. 5,711,962 1/1998 Cordes et al.. 5,741,511 4/1998 Lee et al.. Assignee: Ortho-McNeil Pharmaceutical, Inc., 5,762.956 6/1998 Chien et al.. Raritan, N.J. 5,788,983 8/1998 Chien et al.. Appl. No.: 09/340,859 FOREIGN PATENT DOCUMENTS 0 196 769 10/1986 European Pat. Off.. Filed: Jun. 28, 1999 O 295 411 A1 12/1988 European Pat. Off.. O 454 089 A1 10/1991 European Pat. Off.. Related U.S. Application Data 0 235 259 7/1992 European Pat. Off.. 0 705 097 B1 3/1997 European Pat. Off.. Continuation of application No. 09/165,526, Oct. 2, 1998, 0 655 916 B1 2/1998 European Pat. Off.. which is a continuation of application No. 08/660,024, Jun. WO 96/40087 12/1996 WIPO. 6, 1996, Pat. No. 5,876,746, which is a continuation-in-part of application No.
    [Show full text]
  • For Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies
    Rapid and Sensitive Enzyme-Linked Immunosorbent Assays (ELISAs) for Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies Chatchaporn Uraipong Thesis submitted in partial fulfillment of the requirement for the Degree of Master of Science (Research) School of Chemical Engineering The University of New South Wales September, 2010 ABSTRACT Endocrine disrupting chemicals (EDCs) are chemicals that alter functions of the endocrine system and cause health effects in an intact organism, or progeny, or population, with reproductive, developmental, or carcinogenic consequences. In order to facilitate risk assessment of potential endocrine disrupting steroids that are present in ultra low concentrations in the Australian environment, there is a need to boost the analytical capacity for EDC detection. One strategy is to develop antibody-based techniques that can offer simple, cost-effective and reliable analysis with high throughput capacity and portability for real-time monitoring. This thesis describes the design and synthesis of hapten molecules, raising of specific antibodies, formatting and characterising of a series of sensitive competitive Enzyme-Linked Immunosorbent Assays (ELISAs) for 17β-estradiol (E2), 17α-ethynylestradiol (EE2), ethylestradiol-3-methyl ether (mestranol) and testosterone (T), including validation of their performance as fast and effective water monitoring tools. Application of the developed assays to investigate the levels of the target EDCs in bodies of water and efficiency of water treatment plants in urban and rural areas in New South Wales, Australia, is also discussed. 17α-Ethynylestradiol and related synthetic estrogens, are active ingredients of contraceptive pills and hormone therapy, and have been identified as potent EDCs (Warner and Jenkins, 2007).
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • Appendix E: Hormonal Replacement Therapy Regimens E
    Appendix E: Hormonal Replacement Therapy Regimens E he proportion of post-menopausal women 14 days and a three-day drug-free period) or in who use hormone replacement therapy continuous combination with estrogen. These (HRT) has increased in the United States progestin/estrogen therapies (PERTs) alter the during the last two decades (13). While benefit-risk profile of HRT. Tuse of HRT has increased, the average dose and In the United States, conjugated equine estro- duration of use of postmenopausal estrogens has gen (CEE) (Premarin, Wyeth-Ayerst) is the most decreased until recently (64). This is due in part to commonly used form of estrogen for HRT.1,2 the discovery that the cancer-causing effects of There are a number of other estrogens used for postmenopausal estrogen are related to its dose HRT.3 Table E-1 lists the estrogens either ap- and duration. proved for osteoporosis by the Food and Drug Ad- This appendix describes the range of choice re- ministration or accepted for this use by a garding the dose, routes of administration, and committee of the United States Pharmacopoeia. In combinations of hormones currently in use or un- addition to the estrogens listed in the table, the es- der study as treatment for postmenopausal HRT. trogens quinestrol (Estrovis tablets, Parke-Davis) This appendix also describes the appropriate fol- and chlorotrianisene (TACE capsules, Marion low-up of women on HRT. Finally, this appendix Merrel Dow) are approved by the FDA for treat- describes how dosing regimens may affect com- ment of menopausal symptoms (61). pliance with HRT and describes other factors that affect HRT compliance.
    [Show full text]